Bristol Myers Squibb to provide Eliquis free to Medicaid
The pharma company will donate more than seven tons of its active pharmaceutical ingredient (API) to bolster the American supply chain
The pharma company will donate more than seven tons of its active pharmaceutical ingredient (API) to bolster the American supply chain
BaseLaunch has supported 27 biotech companies across multiple modalities and indications
The NP resin portfolio, indicated by its UL746G-certified prefix, equips manufacturers across industries to meet increasingly stringent regulatory and performance standards
If cleared by regulators, CagriSema would become the first treatment to combine a GLP-1 receptor agonist and a long-acting amylin analogue in a single injection
Convenient subcutaneous option has potential to reach more patients with same clinical benefits as Saphnelo IV infusion
Imsidolimab, an IgG4 IL-36 receptor antagonist, works by inhibiting IL-36 receptor signaling, directly addressing the deficiency in the IL-36RA regulator common in GPP patients
The drug is currently being evaluated in two fully recruited global Phase 3 studies for progressive and tophaceous gout, with results expected in 2026.
More than five drug candidates from his team progressed to human trials including drugs like Rilematovir (Phase IIb), and Bedaquiline
All pending litigation between Biocon Biologics, Regeneron, and Bayer will be dismissed
Subscribe To Our Newsletter & Stay Updated